my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
14-06-2006: Novozymes signed an agreement to acquire Delta Biotechnology Ltd from the sanofi-aventis group. The acquisition is subject to the usual official approvals and is expected to be finalised in the next one to three months. The parties have agreed not to disclose the purchase price.
Delta Biotechnology is a small technology-driven company involved in the research, development, production and sale of microbially produced recombinant proteins. Delta Biotechnology Ltd has 106 employees and a strong position in the market segment of recombinant human albumin, an ingredient used in the biopharmaceutical industry as replacement for human serum albumin.
The company's sales, which are primarily contract-based, amounted to around DKK 100 million in 2005 and have mainly been based on annual sales of Recombumin® for the formulation of biopharmaceutical products. The company also has in its pipeline projects for other quality grades of recombinant albumin and recombinant transferrin, which may be used as ingredients for cell culture media in the future. In addition Delta Biotechnology has developed a platform for producing recombinant proteins based on the Albufusion technology.
Novozymes is taking over Delta Biotechnology Ltd as part of its strategy of acquiring businesses which can strengthen its position and which use the same technology base as Novozymes. The acquisition will underpin the creation of a platform in ingredients for the biopharmaceutical industry. Novozymes already produces and develops ingredients for the biopharmaceutical industry.
Watchlist
This is where you can add this news to your personal favourites
Novozymes and Terranol to market advanced biofuel yeast
Novozymes and Terranol, a Denmark-based biotechnology company specialized in yeast, announced an agreement that will ensure the final optimization of the Terranol C5 yeast strain and give Novozymes the rights to register and market Terranol’s C5 yeast technology. C5 yeast is an essential co ... more
BASF, Cargill and Novozymes target commercial bio-based acrylic acid process
BASF, Cargill and Novozymes have signed an agreement to develop technologies to produce acrylic acid from renewable raw materials.Presently, acrylic acid is produced by the oxidation of propylene derived from the refining of crude oil. BASF, Cargill and Novozymes will develop bio-based tech ... more
Novozymes develops fungus to produce biochemicals
Novozymes has succeeded in developing a fungus that enables production of malic acid from renewable raw materials instead of oil. Malic acid is used as a flavor enhancer in the food industry and can be converted into other chemical derivatives used for a variety of plastic, polymer and resi ... more
Novozymes is the world leader in bio-innovations. Together with customers across a broad array of industries, we create tomorrow's industrial bio-solutions, which both improves our customers' business and the use of the planet's resources more
Oncodesign announced that the company has entered into a strategic research collaboration with Sanofi to apply exclusively Oncodesign’s Nanocyclix(R) technology to several Sanofi kinase target programs. Nanocyclix(R) is a proprietary medicinal chemistry technology and research platform bas ... more
Algeta ASA announced that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a proprietary antibody from Genzyme to create a ... more
Sanofi Canada invests in prostate cancer research
Sanofi Canada is supporting a five-year study on radiation therapy and prostate cancer. Dr. Tamim Niazi of the Quebec Radiation Oncology GU Group and the JGH is the lead researcher. Sanofi Canada President and CEO, Hugh O'Neill and members of Sanofi's Oncology Team celebrate the collaboration. more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Novozymes acquires Delta Biotechnology
Novozymes has acquired Delta Biotechnology Ltd from the sanofi-aventis group. Established in 1984, Delta is now a wholly-owned subsidiary of Novozymes A/S operating as a self-contained business unit with both its R&D and manufacturing facilities based in Nottingham, UK. The new company will ... more
Novozymes acquires Delta Biotechnology Ltd
Novozymes signed an agreement to acquire Delta Biotechnology Ltd from the sanofi-aventis group. The acquisition is subject to the usual official approvals and is expected to be finalised in the next one to three months. The parties have agreed not to disclose the purchase price. Delta Bio ... more
Delta Biotechnology has been recognised with a Queen's Award for Enterprise, the most prestigious award of its kind available to companies in the UK. Delta employs approximately 100 people in Nottingham, UK, and has spearheaded the development of the growing biotechnology industry in the Ea ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
